<DOC>
	<DOCNO>NCT02791438</DOCNO>
	<brief_summary>The purpose study evaluate safety administration TAK-536 pediatric patient age 6 less 16 year hypertension .</brief_summary>
	<brief_title>A Phase 3 Long-term Study TAK-536 Pediatric Patients 6 Less Than 16 Years With Hypertension</brief_title>
	<detailed_description>This phase 3 , open-label , multicenter study evaluate safety , efficacy , pharmacokinetics long-term administration TAK-536 daily 52 week pediatric patient age 6 less 16 year hypertension . The study consist 2-week Run-in Period , 52-week Treatment Period ( Treatment Period I , 12-week ; Treatment Period II , 40-week ) , 2-week Follow-up Period ( 56 week total ) . Participants eligible screen initiate receive placebo single-blinded fashion start Run-in Period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . In opinion investigator subinvestigator , participant 's parent participant 's legal guardian capable understand comply protocol requirement . 2 . The participant 's parent participant 's legal guardian capable sign date write , informed consent form behalf participant prior initiation study procedure . Written inform assent also obtain participant much possible . 3 . The Japanese participant diagnosis hypertension . A participant eligible he/she deem hypertensive accord Reference Blood Pressure Values Children Gender Age ; office sit diastolic systolic blood pressure ≥ 95 percentile essential hypertension without concomitant hypertensive organ damage , ≥ 90 percentile secondary hypertension concomitant CKD , diabetes mellitus , heart failure hypertensive organ damage . In addition , participant need meet follow criterion : 1 . If currently treat antihypertensive drug start Runin Period : Participant document historical diagnosis hypertension office sit diastolic systolic blood pressure meeting criterion end Runin Period ( Week 0 ) . 2 . If currently untreated antihypertensive drug start Runin Period : Participant meet criteria 3 separate time point include screen end Runin Period ( Week 0 ) . In addition , participant essential hypertension without concomitant hypertensive organ damage still maintain hypertension nonpharmacotherapy include food exercise least 3 month within 1 year prior start screening . 4 . The participant male female age 6 less 16 year time inform consent . 5 . The participant weighs least 20 kg screening . 6 . The participant capable take tablet granule supply study drug . 7 . A participant undergone kidney transplantation eligible he/she underwent transplantation least 6 month earlier screening , graft functionally stable ( estimate glomerular filtration rate [ eGFR ] ≥ 30 mL/min/1.73 m2 ) least 6 month evidence ( eg , Doppler echography , CT scan [ compute tomography ] MRI [ magnetic resonance image ] ) exclude graft kidney arterial stenosis . A participant immunosuppressive therapy stable dose least 30 day prior screen eligible . 8 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent 1 month completion study , prove negative pregnancy test screening . 9 . The participant judge investigator subinvestigator he/she discontinue therapy RAS inhibitor 2 week ( acceptable range , 1 4 week ) safe prior Treatment Period . 1 . The participant receive investigational compound within 30 day prior screen participate another clinical study postmarketing clinical study . Note : This apply participants participate observational study without interventional invasive therapy . 2 . The participant previously receive therapy azilsartan . Note : This apply participants participate single dose pharmacokinetic study TAK536 . 3 . The participant poorly control hypertension indicate office sit systolic blood pressure high least 15 mmHg and/or office sit diastolic blood pressure high least 10 mmHg 99 percentile Reference Blood Pressure Values Children Gender Age . 4 . The participant diagnosis malignant accelerate hypertension . 5 . The participant noncompliant ( &lt; 70 % &gt; 130 % ) study drug Runin Period . 6 . The participant severe renal dysfunction ( eGFR &lt; 30 mL/min/1.73 m2 ) , receive dialysis , renovascular disease affect one kidney , severe nephrotic syndrome remission , serum albumin level &lt; 2.5 g/dL . 7 . The participant history , signs/symptoms serious cardiovascular , hepatobiliary , gastrointestinal , endocrine ( eg , hyperthyroidism , Cushing 's syndrome ) , hematological , immunological , urinogenital , psychiatric disease , cancer , disease adversely affect participant 's health , , opinion investigator subinvestigator , potentially confound study result . 8 . The participant hemodynamically significant leave ventricular outflow obstruction due aortic stenosis aortic valvular disease , schedule undergo medical procedure affect blood pressure study ( eg , correction arterial anomaly ) . 9 . The participant history concurrent clinically significant abnormality 12lead ECG , opinion investigator subinvestigator , disqualifies participant participation study . 10 . The participant poorly control diabetes mellitus indicate HbA1c &gt; 9.0 % screening . 11 . The participant alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level ≥ 2.5 × upper limit normal ( ULN ) , total bilirubin level ≥ 1.5 × ULN screening , severely impaired hepatic function , active liver disease ( regardless cause ) , jaundice . 12 . The participant hyperkalemia exceed ULN screening . 13 . The participant history hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) infection screen . 14 . The participant know hypersensitivity allergy ARBs . 15 . The participant need treatment excluded medication . 16 . If female , participant pregnant lactate intend become pregnant , , within 1 month completion study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>